CXCL8 and breast carcinoma: Previous studies have also reported an upregulation of IL-8 in HER2+ breast cancers, which aligns with our findings, where the expression of IL-8 in the HER2+ MDA-IBC3+M0 platform was notably higher compared to the triple-negative SUM149+M0 platforms [48,72,81].